Skip to main content
SpringerLink
Log in

Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ciclosporin ophthalmic emulsion 0.1% (hereafter referred to as ciclosporin 0.1%) [Ikervis®] is an unpreserved cationic emulsion formulation containing an 0.1% concentration of ciclosporin. It has been approved in various countries worldwide, including those of the EU, for the treatment of severe keratitis in adults with dry eye disease, which has not improved despite treatment with tear substitutes. In a multinational, phase III study in this patient population, once-daily ciclosporin 0.1% was associated with statistically significant and clinically relevant improvements in the signs (corneal surface damage and ocular surface inflammation) of dry eye disease relative to vehicle during the first 6-month treatment period. These beneficial effects were maintained or improved in a subsequent 6-month period, with data suggesting sustainability following treatment discontinuation in a 24-month, phase III extension study. Ciclosporin 0.1% was well tolerated in these studies, with instillation-site pain (which was mostly mild in severity) being the most frequently reported ocular treatment-related adverse event. There were no findings to suggest the systemic absorption of ciclosporin. Thus, once-daily ciclosporin 0.1% is an effective and well tolerated option for the treatment of severe keratitis in adults with dry eye disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II introduction. Ocul Surf. 2017;15(3):269–75.

    Article  PubMed  Google Scholar 

  2. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.

    Article  PubMed  Google Scholar 

  3. Baudouin C, Irkec M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol (Copenh). 2017. doi:10.1111/aos.13436.

    Google Scholar 

  4. Lallemand F, Schmitt M, Bourges J-L, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28.

    Article  CAS  PubMed  Google Scholar 

  5. Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2013;32(3):345–54.

    Article  PubMed  Google Scholar 

  6. Lyseng-Williamson KA. Cationorm® (cationic emulsion eye drops) in dry eye disease: a guide to its use. Drugs Ther Perspect. 2016;32(8):317–22.

    Article  Google Scholar 

  7. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531–41.

    Article  CAS  PubMed  Google Scholar 

  8. Daull P, Guenin S, Garrigue JS. Mechanism of action of cationic emulsions in the management of ocular surface inflammation and wound healing [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):5053.

    Google Scholar 

  9. European Medicines Agency. Ikervis (ciclosporin): EU assessment report. 2015. http://www.ema.europa.eu/ema/. Accessed 26 Sep 2017.

  10. Santen Oy. IKERVIS 1 mg/mL eye drops, emulsion: EU summary of product characteristics. 2017. http://www.ema.europa.eu/ema/. Accessed 26 Sep 2017.

  11. Ambroziak AM, Szaflik J, Szaflik JP, et al. Immunomodulation on the ocular surface: a review. Cent Eur J Immunol. 2016;41(2):195–208.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Daull P, Feraille L, Barabino S, et al. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res. 2016;153:159–64.

    Article  CAS  PubMed  Google Scholar 

  13. Garrigue JS, Daull P, Feraille L, et al. Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):421.

    Google Scholar 

  14. Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–30.

    Article  PubMed  Google Scholar 

  15. Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–96.

    Article  PubMed  Google Scholar 

  16. Baudouin C, Sainz de la Maza M, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017. doi:10.5301/ejo.5001002.

    Google Scholar 

  17. Leonardi A, Garhöfer G, Amrane M, et al. Persistence of efficacy of 0.1% ciclosporin A cationic emulsion in subjects with severe keratitis due to dry eye disease [abstract no. EX1-051 plus poster]. In: 32nd Asia-Pacific Academy of Ophthalmology Congress. 2017.

  18. Messmer E, Leonardi A, Amrane M, et al. Pooling of two randomized phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED) [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):2871.

    Google Scholar 

  19. Garrigue JS, Messmer EM, Leonardi A, et al. Meta-analysis of two phase III clinical trials of 0.1% ciclosporin cationic emulsion in dry eye disease patients with severe keratitis [poster 266]. In: 29th Annual Meeting of Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS). 2016.

  20. Leonardi A, Garhöfer G, Amrane M, et al. Subgroup analysis of two phase III studies of 0.1% cyclosporine A cationic emulsion (CsA CE) in patients with dry eye disease [abstract no. S064]. Acta Ophthalmol (Copenh). 2016;94(Suppl):S256.

  21. Doan S, Pisella PJ, Cochener B, et al. Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: experience through the French early access program [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):2876.

    Google Scholar 

  22. Santen Pharmaceutical (China) Co. Ltd. IKERVIS 1 mg/mL eye drops, emulsion: Hong Kong prescribing information. Beijing: Santen Pharmaceutical (China) Co. Ltd.; 2015.

  23. Santen Pharmaceutical Korea Co. Ltd. IKERVIS 1 mg/mL eye drops, emulsion: South Korean prescribing information. Seoul: Santen Pharmaceutical Korea Co. Ltd.; 2017.

  24. Santen Pharmaceutical Asia Pte. Ltd. IKERVIS eye drops, emulsion 1 mg/mL: Singapore prescribing information. Singapore: Santen Pharmaceutical Asia Pte. Ltd.; 2017.

  25. Santen (Thailand) Co. Ltd. IKERVIS eye drops, emulsion (ciclosporin 1 mg/mL): Thailand prescribing information. Bangkok: Santen (Thailand) Co. Ltd.; 2015.

  26. Novack GD, Asbell P, Barabino S, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017;15(3):629–49.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of ciclosporin ophthalmic emulsion 0.1% was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/780CF06039AC338F.

Additional information

The manuscript was reviewed by: S. Bonini, Department of Ophthalmology, University Campus Bio-Medico of Rome, Rome, Italy; A. Leonardi, Ophthalmology Unit, Department of Neuroscience, University of Padua, Padua, Italy; M. Sainz de la Maza, Clinical Institute of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; J. S. Wolffsohn, Ophthalmic Research Group, School of Life and Health Sciences, Aston University, Birmingham, UK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. Drugs 77, 1909–1916 (2017). https://doi.org/10.1007/s40265-017-0834-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0834-x

Search

Navigation